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In Brief
Tau dysfunction causes
neurodegeneration, and tau pathology
spreading appears to occur along
synaptically connected neurons.
However, it is not known whether the
actual presence of synapses enhances
spreading. Using artificial neuronal
circuits in vitro, Calafate et al. show that
synaptic contacts promote spreading
and that synaptic and non-synaptic
mechanisms act in parallel.
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Accumulation of insoluble Tau protein aggregates
and stereotypical propagation of Tau pathology
through the brain are common hallmarks of tauo-
pathies, including Alzheimer’s disease (AD). Propa-
gation of Tau pathology appears to occur along
connected neurons, but whether synaptic contacts
between neurons are facilitating propagation has
not been demonstrated. Using quantitative in vitro
models, we demonstrate that, in parallel to non-syn-
aptic mechanisms, synapses, but not merely the
close distance between the cells, enhance the prop-
agation of Tau pathology between acceptor hippo-
campal neurons and Tau donor cells. Similarly, in
an artificial neuronal network using microfluidic de-
vices, synapses and synaptic activity are promoting
neuronal Tau pathology propagation in parallel to
the non-synaptic mechanisms. Our work indicates
that the physical presence of synaptic contacts be-
tween neurons facilitate Tau pathology propagation.
These findings can have implications for synaptic
repair therapies, which may turn out to have adverse
effects by promoting propagation of Tau pathology.INTRODUCTION
Tauopathies are a diverse group of neurodegenerative diseases
defined by the accumulation of misfolded cytosolic aggregates
of the microtubule-associated protein Tau. Alzheimer’s disease
(AD) is the most common tauopathy (Holtzman et al., 2011).
Tau aggregates first appear in the locus coeruleus and gradually
propagate via the entorhinal cortex to hippocampus and the
neocortex. This typical temporo-spatial progression of Tau pa-
thology provides the basis for the classical Braak disease stag-
ing in AD (Braak and Del Tredici, 2011, 2012; Jucker andWalker,
2013). Recent evidence suggests that the progression of Tau pa-
thology is determined by intrinsic characteristics and vulnera-
bility of anatomically connected neurons (Hardy and Revesz,
2012), supporting the idea that intracellular Tau aggregates arereleased from the originating neuron and taken up by a neigh-
boring connected neuron. These observations indicate that
neuronal synaptic contacts may be involved in Tau pathology
propagation (Brettschneider et al., 2015), but this idea has not
been experimentally addressed.
In vitro studies show that neuronal activity can modulate Tau
protein secretion into the extracellular space (Pooler et al.,
2013; Yamada et al., 2014). Extracellular Tau aggregates can
directly penetrate adjacent cell membranes or can be internal-
ized via fluid-phase endocytosis or receptor-mediated endocy-
tosis (Clavaguera et al., 2009; Frost et al., 2009; Guo and Lee,
2011, 2013; Holmes et al., 2013). In addition, recombinant pre-
formed synthetic Tau fibrils move anterogradely and retro-
gradely within a neuron (Scholz and Mandelkow, 2014; Wu
et al., 2013). A recent in vivo study provides further support for
the concept that Tau pathology progression involves circuit-
based transfer of Tau aggregates (de Calignon et al., 2012; Liu
et al., 2012). However, it remains to be determined whether
Tau pathology propagation is a consequence of cell damage
or is mediated by synaptic regulated mechanisms.
Here, we use in vitro models where Tau pathology propagates
from a donor clonal cell line that persistently harbors Tau aggre-
gates to acceptor hippocampal neurons. We find that this trans-
fer is significantly potentiated when we induce the formation
of presynaptic contacts from neurons onto the clonal cells.
Furthermore, by generating artificial neuronal networks in micro-
fluidic devices that allow separation of the somatodendritic com-
partments from the axonal compartments, we find that synaptic
contacts and neuronal activity potentiate neuron-to-neuron
propagation of Tau pathology.RESULTS
HEK293 Cells Persistently Form Tau Aggregates
To study the propagation of Tau pathology in a cellular system,
we developed a clonal cell-to-neuron transmission model. We
co-cultured HEK293 cells persistently harboring intracellular
Tau aggregates with rat hippocampal neurons. These HEK293
cells with Tau aggregates were derived from a polyclonal
HEK293 cell line with inducible expression of a GFP-tagged
human mutant P301L Tau (TauP301L-GFP; ‘‘clone 1’’; Fig-
ure S1A). Aggregation of TauP301L-GFP was induced by adding
Figure 1. Tau Pathology Propagates from
HEK293 with Aggregates to Hippocampal
Neurons
(A and B) Confocal analysis of clone 1 or clone 2
cells co-cultured at DIV7 with hippocampal neu-
rons expressing TauP301L and fixed at DIV12–14
in 4% PFA or 4% PFA 1% Triton X-100 im-
munolabeled for total Tau using hT7 or for phos-
pho-Tau using AT8 antibody (magenta) and MAP2
(white) antibodies. DAPI, nuclei (blue). The scale
bar represents 50 mm. (A) Hippocampal neurons
co-cultured with clone 2 show Triton-X-100-
resistant TauP301L aggregates in hippocampal
neurons (magenta; arrow). (B) Hippocampal neu-
rons co-cultured with clone 1 cells do not show
AT8 immunoreactivity.
(C) AlphaLISA for aggregated HA-tagged neuronal
Tau of fractions of hippocampal neurons ex-
pressing HA-TauP301L co-culturedwith clone 2 at
DIV7 and lysed in 1% Triton X-100 (error bars:
SEM; n = 4; ****p < 0.0001).
(D) Fractions as in (C) analyzed by western blot.
Total HA-TauP301L (expressed in neurons) was
detected using anti-HA, and total TauP301L-GFP
(expressed in HEK293 cells) was detected using
anti-GFP. Arrows, insoluble HA-TauP301L and
TauP301L-GFP. n = 4.
Related to Figure S1.recombinant preformed synthetic HA-K18P301L fibrils as des-
cribed before (Guo and Lee, 2011). These cells were diluted,
and sub-clones were isolated. To assess whether clones that
stably replicate Tau aggregates can be identified (now in the
absence of exogenously added HA-K18P301L fibrils), cells
were fixed and soluble protein extracted and remaining insoluble
inclusions were labeled with AT8, a monoclonal anti-Tau anti-
body that recognizes hyperphosphorylated Tau protein (Vander-
meeren et al., 1993). One of the clones (‘‘clone 2’’) constitutively
showed AT8-positive juxtanuclear aggregates and cytosolic
speckles (Figure S1B), indicating that Tau aggregates are self-
replicative over cellular generations. Biochemical characteriza-
tion of clone 1 and 2 using semi-denaturing detergent agarose
gel electrophoresis (SDD-AGE) showed that, along with mono-
meric Tau, clone 2 also contains higher-molecular-weight
Tau species (Figure S1C). The aggregated nature of thesehigher-molecular-weight Tau species
was further demonstrated by sedimenta-
tion analysis and confirmed by western
blot (Figure S1D). Our results indicate
that, once Tau forms aggregates in cells,
they are replicated over generations
(Clavaguera et al., 2013; Sanders et al.,
2014).
Clonal Cell-to-Neuron Tau
Pathology Propagation
To examine whether Tau pathology can
propagate from clonal HEK293 donor
cells to a neuronal acceptor population,
we co-cultured clone 2 cells with hippo-campal neurons (DIV7) expressing human mutant P301L Tau
(TauP301L; not GFP tagged). About 10% of the neurons devel-
oped Tau aggregates as evident from the AT8-positive and
Triton X-100 extraction-resistant nature of the inclusions after
5–7 days of co-culture (Figure 1A). These aggregates were
GFP negative and co-localized with MAP2, indicating that these
represented aggregates derived from human TauP301L ex-
pressed in these neurons. In contrast, neurons co-cultured
with clone 1 did not develop Tau aggregates (Figure 1B).
Next, we further explored the biochemical properties of the
Tau aggregates found in hippocampal neurons. Clone 1 and
clone 2 cells were co-cultured with hippocampal neurons
(DIV7) expressing HA-tagged TauP301L (HA-TauP301L), and to-
tal lysates were fractionated into soluble and insoluble fractions
at 5–7 days of co-culture. The fractions were then analyzed by an
AlphaLISA assay (see Experimental Procedures) that selectively
Figure 2. Nlgn1 and LRRTM2 Induce Presynaptic Contacts and Enhance Tau Pathology Propagation
(A) Synapsin labeling (green) of primary hippocampal neurons transduced with TauP301L at DIV2 and co-cultured with HEK293 clone 2 cells transfected to
express adhesion molecules and dsRed (magenta) at DIV7. The scale bar represents 20 mm.
(B) Quantification of the area occupied by synapsin on the HEK293 cell surface. Error bars: SEM; vector (n = 74); N-Cdh (n = 80); Nlgn1 (n = 40); LRRTM2 (n = 74);
DLRR (n = 40). ANOVA/Tukey’s: ****p < 0.0001.
(C) TEM of co-cultures as in (A), pseudocolored to reveal presynaptic contacts (blue; synaptic vesicles, arrow) onto clone 1 or 2 cells expressing LRRTM2 (green).
The scale bar represents 100 nm.
(D) AlphaLISA of aggregated HA-Tau of co-cultures of primary hippocampal neurons transduced with HA-TauP301L at DIV2 and HEK293 clone 2 cells trans-
fected to express adhesion molecules. Error bars: SEM. Vector (n = 8); N-Cdh (n = 6); Nlgn1 (n = 6); LRRTM2 (n = 6); LRRTM2DLRR (n = 4). ANOVA/Tukey’s:
**p < 0.01; ***p < 0.001.
(E) Quantification of the area occupied by b-III-tubulin as in (B). Error bars: SEM; vector (n = 74); N-Cdh (n = 80); Nlgn1 (n = 40); LRRTM2 (n = 74); LRRTM2DLRR
(n = 40). ANOVA/Tukey’s: ****p < 0.0001.
Related to Figure S2.detects aggregated HA-TauP301L from the neurons, but not
clone-2-derived Tau aggregates (TauP301L-GFP). High levels
of HA-TauP301L aggregates were only detected using the Al-
phaLISA assay in the total and insoluble fractions from the co-
culture of hippocampal neurons with clone 2, but not with clone
1 (Figure 1C). These results were further confirmed by western
blot (Figure 1D). These results indicate that Tau pathology can
propagate from a clonal cell to a primary neuronal cell.
Synaptogenic Molecules Potentiate Clonal
Cell-to-Neuron Tau Pathology Propagation
To test whether Tau propagation is enhanced by the formation of
synaptic contacts, we expressed, in the clonal cells, the synaptic
cell adhesion molecules neuroligin 1 (Nlgn1) and leucine-rich
repeat trans-membrane protein 2 (LRRTM2) that bind neurexin
and are expected to induce presynaptic differentiation in con-tacting axons of co-cultured neurons (Linhoff et al., 2009; Scheif-
fele et al., 2000; Su¨dhof, 2008; deWit et al., 2009). Indeed, immu-
nolabeling of the co-cultures indicated the accumulation of
presynaptic markers (synapsin) when HEK293 cells harboring
constant Tau aggregation were expressing Nlgn1 or LRRTM2,
but not when the cells were transfected with an empty vector
(Figures 2A and 2B). In addition, transmission electron micro-
scopy revealed neuron-to-clone 2 cells synaptic contacts with
presynaptic densities and clusters of synaptic vesicles in prox-
imity to the presynaptic membranes, indicating a presence of
active zones (Figure 2C).
We then used our AlphaLISA assay to assess whether
HA-TauP301L aggregated in the hippocampal neurons. As ex-
pected, co-culturing the Nlgn1- or LRRTM2-expressing clone 1
cells with HA-TauP301L-expressing hippocampal neurons did
not result in Tau aggregates (Figure S2A). By contrast, when
we co-cultured Nlgn1- or LRRTM2-expressing clone 2 cells with
HA-TauP301L-expressing hippocampal neurons, we observed
HA-TauP301L aggregation (Figure 2D). The amount of Tau ag-
gregation in neurons after generating synaptic contacts using
Nlgn1 or LRRTM2 was almost 50% higher than when the neu-
rons were co-cultured with clone 2 cells transfected with a
control vector (Figure 2D). This increase in HA-TauP301L aggre-
gation was not simply due to differences in TauP301L-GFP
secreted into culture medium or expression levels in donor clone
2 cells transfected with the adhesion molecules (Figures S2B–
S2D) but due to the increased number of synaptic contacts.
Indeed, when we co-cultured the hippocampal neurons with
clone 2 cells that express LRRMT2DLRR, an LRRTM2 mutant
that fails to induce synaptogenesis (Figures 2A and 2B) (de Wit
et al., 2009), we did not observe the increase in HA-TauP301L
aggregation (Figure 2D). Finally, the increased HA-TauP301L ag-
gregation is also not merely the result of the increased cellular
contact surface. Here, we used expression of cell adhesion
molecule N-Cadherin (N-Cdh) that induced an increase in cell-
neuron contacts, but not an increased number of synapses
(Scheiffele et al., 2000) (Figures 2B and 2E), and this condition
did not result in an increase in HA-TauP301L aggregation (Fig-
ure 2D). Hence, these results suggest that synaptic contacts
induced by expression of synaptogenic adhesion proteins en-
ables an additional and distinct mechanism of Tau propagation
above and beyond the baseline propagation observed in this
cell-to-neuron model in the absence of synaptic contacts.
Neuron-to-Neuron Tau Pathology Propagation Is
Facilitated by Synaptic Connectivity
We next sought to assess whether synaptic contacts between
neurons also promote Tau pathology propagation. Hippocampal
neurons expressing human mutant P301L Tau (TauP301L) were
exposed to synthetic HA-K18P301L fibrils at DIV5 (Guo and Lee,
2013; Sanders et al., 2014). As expected, these neurons devel-
oped Tau aggregates derived from the expressed human
TauP301L, as was evident from robust AT8-positive and Triton
X-100 extraction-resistant TauP301L inclusions (the AT8 epitope
is absent in HA-K18P301L fibrils; Figure S3A). To examine the
propagation of Tau aggregation in neuronal cultures, we resorted
tomicrofluidic culture devices that allowed us to physically sepa-
rate the somatodendritic and axonal areas (Taylor et al., 2005).
The devices consist of three fluidic isolated chambers (C1–3)
connected by microgrooves. Axons, but not dendrites, can proj-
ect through microgrooves, and axons are expected to form syn-
aptic contacts with the somatodendritic compartment of the
neuron in the chambers to where they extend, thereby forming
an artificial neuronal circuit between the chambers. Axons of
neurons plated in C3 reach C2 at DIV15, but at this stage, we
never detected neurons that reached over to C1 (Figure S3B).
We plated hippocampal neurons in all three chambers (C1,
2, and 3) and transduced the cells with TauP301L at DIV2.
Next, Tau pathology was induced in C1 by seeding with
HA-K18P301L fibrils at DIV5. At DIV12, Tau aggregates were de-
tected in neurites as well as neuronal cell bodies in both C1 and
C2 whereas they were absent in C3 cell bodies (Figure 3A). At
DIV15, lower quantities of Tau aggregates were also detectable
in neurites as well as neuronal cell bodies in C3 (Figure 3B). Thiseffect is not because the HA-K18P301L fibrils added in C1 are
diffusing across chambers because (1) pressure is higher in C3
than in C1 blocking diffusion to C3 and (2) even after prolonged
time periods (DIV15), we were unable to detect these exoge-
nously added HA-K18P301L fibrils in C2 or C3 (Figure S3C).
To test the importance of synaptic contacts for the propaga-
tion of Tau pathology, we sought to interrupt the neuronal circuit
formed between these chambers. We only plated neurons in C1
and C3 because, in this situation, the absence of somatoden-
dritic compartments in C2 prevents the neurons that project
from C1 and C3 from forming synapses in C2 (Figure 3C).
HA-K18P301L fibrils were added to C1, and robust induction
of Tau aggregation was observed in somatodendritic areas of
neurons in C1 and within the axons that projected from C1 to
C2. However, at DIV15, we did not detect substantial Tau aggre-
gation in C3 neurons (Figures 3C–3E). Hence, Tau pathology
propagation to neurons in C3 is enhanced when synapses are
allowed to form in C2.
Efficient Neuron-to-Neuron Tau Pathology Propagation
Is Promoted by Synaptic Connections and Neuronal
Activity
To further address the involvement of synaptic connectivity
in promoting neuron-to-neuron Tau propagation, we blocked
the formation of synapses with neurons in C2. We used shRNA
to knock down the synaptogenic cell adhesion molecules
Nlgn1, 2, and 3 (sh-Nlgn1, sh-Nlgn2, and sh-Nlgn3; Figure S4A).
Reduced expression of Nlgn1, 2, or 3 resulted in synaptic
density decrease (Figures S4B and S4B’) as observed previ-
ously (Chih et al., 2005) without inducing cellular toxicity (Fig-
ure S4D). Hippocampal neurons were plated in all three
chambers (C1-2-3) and transduced with TauP301L. Neurons
in C2 and C3 were also additionally transduced with shRNA
for Nlgn1, 2, or 3 or a control shRNA at DIV2. Neurons in
C1 were seeded with HA-K18P301L fibrils at DIV5, and
Tau aggregation in the three chambers was assessed by
alphaLISA. Reduction of synaptic connectivity upon expression
of shNlgn1, 2, and 3 resulted in a significant decrease of total
aggregated Tau in C3 as compared to expression of a control
shRNA (Figures S4A and 4A).
To examine the potential role of synaptic activity within the
neurons of this mini-circuit, we incubated the cells in C2 and
C3 with the sodium channel blocker tetrodotoxin (TTX), a manip-
ulation that blocks neuronal activity (Murthy et al., 2001) but does
not affect synapse density (Figure S4C) or cause cellular toxicity
(Figure S4E).We then induced Tau aggregation by incubating the
cells in C1 with HA-K18P301L fibrils and observed a significant
decrease in the amount of aggregated Tau developed in the neu-
rons in C3 at DIV15 (Figure 4B). We believe Tau aggregation
levels in C2 are not affected by Nlgn knockdown or TTX because
these neurons can project into C1, taking up HA-K18P301L.
Thus, neuronal propagation of Tau pathology is promoted by
synaptic connectivity as well as neuronal activity.
DISCUSSION
The observations reported here show that Tau propagation be-
tween cells is significantly facilitated by synaptic connections.
Figure 3. Neuron-to-Neuron Tau Pathology Propagation Is Facilitated by Synapses
(A) Hippocampal neurons incubated with HA-K18P301L fibrils (in C1 at DIV5) and transduced with TauP301L (C1–3; DIV2), fixed and extracted with 4% PFA and
1% Triton X-100 (DIV12), and labeled with phospho-Tau AT8 antibody (white) and DAPI (nuclei). The scale bar represents 50 mm.
(B) Experiment as in (A), but cells were fixed at DIV15.
(C) Experiment as in (A) without neurons in C2.
(D) Quantification of hippocampal neurons containing TauP301L aggregates in C3 from conditions (B) and (C). Error bars: SEM; C1, 3 (n = 4); C1, 2, 3 (n = 3).
Student’s t test; ***p < 0.001.
(E) Quantification of the TauP301L pathology propagation to neurons in C3 using AlphaLISA from conditions (B) and (C) normalized to actin protein loading control
and expressed as percentage of aggregated TauP301L. Error bars: SEM; C1, 3 (n = 8); C1, 2, 3 (n = 10). Student’s t test; **p < 0.01.
Related to Figure S3.Using a unique in vitro model for Tau pathology propagation,
we find that the expression of synaptogenic proteins in heterol-
ogous cells containing Tau aggregates potentiates Tau propaga-
tion from these cells to co-cultured hippocampal neurons.
We extend these findings to demonstrate Tau pathology propa-
gation between synaptically connected neurons using the
microfluidic chamber setup. Additionally, we show decreased
synaptic density or suppressed synaptic activity weakens
neuron-to-neuron Tau pathology propagation.In one of our co-culture models, Tau pathology propagates
from the clonal HEK293 donor cell to the hippocampal neuron
acceptor cells that consequently develop Tau aggregation. In
this baseline condition, propagation is mediated via an unknown
mechanism that might involve the release of a ‘‘seed’’ from the
donor cell to the extracellular medium followed by entry into
the recipient neuron (Kfoury et al., 2012). The stereotypical prop-
agation of Tau pathology within the brain between connected
neurons has led to the postulation that the propagation can be
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Figure 4. Decrease in Synapse Formation and Synapse Activity
Reduces Neuron-to-Neuron Tau Pathology Propagation
Hippocampal neurons in C1, 2, and 3 transduced with TauP301L on DIV2 and
HA-K18P301L fibrils added on DIV5 in C1.
(A) Hippocampal neurons in C2 and C3 were also transduced with control
shRNA or shRNA for Nlgn1, 2, and 3. Cells from each channel were lysed, and
aggregated TauP301L was quantified by AlphaLISA. Error bars: SEM; n = 6.
Student’s t test; *p < 0.05.
(B) Hippocampal neurons in C2 and C3 were chronically exposed to TTX from
DIV5 to 15, and aggregated TauP301L was quantified by AlphaLISA.
Aggregated TauP301L in C3 in (A) and (B) is normalized to actin protein
loading control and expressed as percentage of aggregated TauP301L; error
bars: SEM; control (n = 10); TTX (n = 5). Student’s t test: *p < 0.01. Related to
Figure S4.synapse mediated (Braak and Del Tredici, 2011; de Calignon
et al., 2012; Liu et al., 2012). Here, we now provide several lines
of evidence in favor of this idea becausewe are able to follow Tau
propagation while specifically modulating the synaptic contacts
between cells. First, the generation of synaptic contacts be-
tween donor cells and the acceptor neuron causes the Tau pa-
thology propagation to increase by almost 50%. Furthermore,
we demonstrate that synaptogenic mechanisms also promoted
Tau pathology dissemination within an artificial neuronal
network. The presence of abnormal Tau within the pre- and
post-synaptic compartments of AD brains supports the idea
that this species can be a substrate for trans-synaptic transmis-sion (Tai et al., 2014). We therefore hypothesize that a form of
Tau-seeding species that is present at the synapse can be
trans-synaptically transmitted to connected neurons, thereby
disseminating Tau pathology by inducing aggregation of soluble
Tau (Guo and Lee, 2014; Tai et al., 2014). In future work, the
mechanism by which such seeding species are transmitted
across the synapse can now be discovered.
The co-culture systems presented here are a considerable
improvement over the standard Tau-fibril-seeding models that
require constant addition of exogenously added seeds. The
cell-neuron model could potentially be employed in unbiased
screenings to unveil potential pre- and post-synaptic players
that drive Tau propagation, such as adhesion molecules, mem-
brane receptors, as well as other proteins of the synaptic ma-
chinery that sustain synaptic activity. In addition, the neuronal
model allows for the generation of a neuronal network that en-
ables the study of seeding and propagation of Tau pathology
in a more physiologically relevant system.
Evidence converges on the idea that synaptic degeneration is a
major pathophysiological feature of neurodegenerative diseases
(Lu et al., 2013; Serrano-Pozo et al., 2011). In AD, synapse loss
strongly correlates with cognitive decline and both Ab and Tau
are identified key pathogenic players (Selkoe, 2002; Spires-Jones
and Hyman, 2014). Therefore, disease-modifying therapies that
focus on rescuing synaptic dysfunction and synapse rejuvenation
are emerging (Lu et al., 2013; Peretti et al., 2015). However, our
data suggest that synapses can also be an avenue for enhanced
Tau propagation. Therefore, therapeutic strategies that are de-
signed to target pathophysiology should be accompanied by
strategies that target pathogenesis, for example, by specifically
blocking synapse-mediated Tau propagation or by boosting
clearance of Tau aggregates that are internalized at the synapse.
Our observations are consistent with the ‘‘cell-to-cell transmis-
sion hypothesis’’ of Tau pathology and reveals that synapses
are actively involved in the transmission of Tau pathology.
EXPERIMENTAL PROCEDURES
Primary Antibodies
Primary antibodies are mouse anti-hT7 (Sigma-Aldrich; S5062); mouse
anti-human Tau 10 (hTau10; epitope 29–36); mouse anti-AT8 (pSer202/
Thr205); rabbit anti-synapsin (Millipore; AB1543P); rabbit anti-PSD95
(Millipore; MA1-046); chicken anti-Map2 (Abcam; ab5392); chicken anti-b-III-
tubulin (Abcam; ab41489); mouse anti-III b-tubulin (Covance; mms-435p);
rabbit anti-HA (Invitrogen; 71-5500); rabbit anti-FLAG (Sigma-Aldrich;
F3165); mouse anti-GFP (Sigma-Aldrich; G1546); mouse anti-LRRTM2
(NeuroMab; 73-364); mouse anti-actin (Millipore; MAB1501); and rabbit anti-
Nlgn1, 2, and 3 (Synaptic Systems; 129013, 129203, and 129103). Immunolab-
eling, western blots, and semi-denaturing PAGE were performed as described
in the Supplemental Information.
Primary Cultures
Hippocampal neurons were cultured from E17 to E18 Wistar rat embryos
(Charles River Laboratories). Transductions with the plasmids of interest
(see Supplemental Experimental Procedures) were performed at DIV2. For
biochemistry, neurons were plated in poly-d-lysine-coated plates (BD Bio-
Coat). For immunofluorescence, neurons were plated on coverslips coated
with poly-D-lysine (Sigma-Aldrich) and laminin (Sigma-Aldrich). Neurons
were maintained in Neurobasal-A medium (Invitrogen) supplemented with
B27and glutamine. All cultures were maintained at 37C and 5% CO2. Cyto-
toxicity assays were performed as described in the Supplemental Information.
Microfluidic Chambers
Triple-compartment microfluidic chambers (Xona Microfluidics) were placed
on coated coverslips, and 60,000 neurons were plated per channel. Transduc-
tions with plasmids of interest (see Supplemental Experimental Procedures)
were performed at DIV2. Cultures were maintained at 37C and 5% CO2 up
to 15 days.
Fibril Preparation and Transduction
Truncated human Tau fragments containing the four microtubule-binding
repeat domains (K18; residues Q244–E372 of the longest human Tau isoform)
with a P301L mutation and N-terminal HA tag (HA-K18P301L) were produced
in Escherichia coli (Tebu-bio). For in vitro fibril production, a solution of 40 mM
HA-K18P301L, 40 mM low-molecular-weight heparin (Sigma-Aldrich), and
2 mM DTT in 100 mM sodium acetate buffer (pH 7.0) was incubated at 37C
for 3 days. The mixture was centrifuged at 100,000 3 g for 30 min at 4C,
and the pellet, which contained the HA-K18P301L fibrils, was re-suspended
in the same volume of sodium acetate buffer. HA-K18P301L fibrils were son-
icated with 25 pulses of 2 s and added to culture medium in a final concentra-
tion of 50 nM.
Mixed Culture
Mixed-culture assays were performed as described in Biederer and Scheiffele
(2007). In brief, clones 1 and 2 (see Supplemental Experimental Procedures)
were transfected with the plasmid of interest (Supplemental Experimental Pro-
cedures) using Fugene6 (Promega). 24 hr after, they were trypsinized for 5 min
at 37C and re-suspended in DMEM medium. Transfected cells were co-
cultured with DIV7 hippocampal neurons for 7 to 8 days. For synaptic contacts
analysis, transfected cells were co-cultured with DIV7 hippocampal neurons
for 48 hr.
Sedimentation
Cells were lysed in PBS containing 1% Triton and cOmplete mini protease in-
hibitor tablet (Roche) and clarified by centrifugation (1,0003 g) for 10 min. Part
of the lysate was kept for total fraction, and the other part was centrifuged at
100,0003 g at 4C for 1 hr. The supernatant was used as soluble fraction. The
pellet was re-suspended in 1% Triton, and a second centrifugation at 100,000
3 g at 4C for 1 hr was done. Supernatant was discarded and the pellet re-sus-
pended in 1% LDS buffer and used as insoluble fraction.
AlphaLISA Immunoassay
Culture medium or pre-cleared lysates (see Sedimentation) sample was
incubated for 2 hr at 37C with the AlphaLISA capturing mixture containing
antibody conjugated biotin and acceptor beads. Next, AlphaLISA detection
mixture containing streptavidin-conjugated donor beads was added and incu-
bated for 1 hr at 37C. AlphaLISA signal was detected with Envision plate
reader (PerkinElmer). To specifically detect aggregated Tau, components of
capturing mixture (biotin/acceptor beads) were conjugated to the same anti-
body: for untagged TauP301L, mouse anti-hT10 was used, and for aggregated
HA-TauP301L, mouse anti HA (Roche Life Science; 12CA5) was used.
TTX Treatment of Hippocampal Neuronal Cultures
Hippocampal neurons in microfluidic devices were chronically treated with
1 mM TTX (Sigma) in normal medium from DIV5 to DIV15.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
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